- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07222553
Studie for å evaluere farmakokinetikk, farmakodynamikk, sikkerhet og tolerabilitet av Inebilizumab hos pediatriske deltakere med IgG4-RD
Åpen merket, ukontrollert, multisentrisk studie for å evaluere farmakokinetikken, farmakodynamikken, sikkerheten og toleransen til inebilizumab hos barn fra 2 år til under 18 år med immunglobulin G4-relatert sykdom (IgG4-RD)
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Amgen Call Center
- Telefonnummer: 866-572-6436
- E-post: medinfo@amgen.com
Studiesteder
-
-
Ceará
-
Fortaleza, Ceará, Brasil, 60140-025
- Rekruttering
- Centro Oncologia Leonardo Da Vinci
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 40110-060
- Rekruttering
- Universidade Federal da Bahia - Hospital Universitario Professor Edgard Santos
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
- Rekruttering
- Hospital de Clinicas de Porto Alegre
-
-
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- University of South Florida - Carol and Frank Morsani Center for Advanced Health Care
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- Rekruttering
- University of North Carolina at Chapel Hill
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- Rekruttering
- University of Pittsburgh Medical Center Childrens Hospital of Pittsburgh
-
-
-
-
-
Athens, Hellas, 11527
- Rekruttering
- General Children Hospital Panagioti and Aglaias Kyriakou
-
Athens, Hellas, 11521
- Rekruttering
- Euroclinic Children Hospital
-
-
-
-
-
Roma, Italia, 00165
- Rekruttering
- IRCCS Ospedale Pediatrico Bambino Gesu
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100730
- Rekruttering
- Peking Union Medical College Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kina, 401122
- Rekruttering
- Childrens Hospital of Chongqing Medical University
-
-
Hunan
-
Changsha, Hunan, Kina, 410000
- Rekruttering
- The Second Xiangya Hospital of Central South University
-
-
-
-
-
Warsaw, Polen, 02-637
- Rekruttering
- Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
-
Warsaw, Polen, 04-730
- Rekruttering
- Instytut Pomnik-Centrum Zdrowia Dziecka
-
Wroclaw, Polen, 52-114
- Rekruttering
- Szpital Specjalistyczny Im A Falkiewicza we Wroclawiu
-
-
-
-
Valencia
-
Valencia, Valencia, Spania, 46026
- Rekruttering
- Hospital Universitari i Politecnic La Fe
-
-
-
-
-
Ankara, Tyrkia (Türkiye), 06100
- Rekruttering
- Hacettepe Universitesi Tip Fakultesi Hastanesi
-
Istanbul, Tyrkia (Türkiye), 34098
- Rekruttering
- Istanbul Universitesi Cerrahpasa Tip Fakultesi
-
Istanbul, Tyrkia (Türkiye), 34764
- Rekruttering
- Umraniye Egitim ve Arastirma Hastanesi
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Participants must weigh ≥ 17 kg to be eligible for enrollment.
- Participant has provided informed consent/assent before initiation of any study-specific activities/procedures. Participant's legally authorized representative has provided informed consent when the participant is legally too young to provide informed consent, and the participant has provided written assent based on local regulations and/or guidelines before any study-specific activities/procedures being initiated.
- Age 2 to < 18 years at the time of screening. For participants who reach the age of legal consent during the clinical study, notification will be required, and a new consent form must be signed by the participant for continuation in the study.
- Clinical diagnosis of IgG4-RD.
- Fulfillment of the 2019 American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) classification criteria as determined by the principal investigator (PI) at screening. Specifically, participants must meet the classification criteria entry requirements (including involvement of one of the following organs: pancreas, bile ducts/biliary tree, orbits, lungs, kidneys, lacrimal glands, major salivary glands, retroperitoneum, aorta, pachymeninges, or thyroid gland [Riedel's thyroiditis]), must not meet any of the classification criteria exclusions, and must achieve at least 20 classification criteria inclusion points.
- Receipt of all age-appropriate and locally-required vaccinations before screening.
- Participants requiring treatment in addition to or other than glucocorticoids (GCs) for IgG4-RD according to PI's assessment at screening.
- Participants who are on GCs for the treatment of IgG4-RD should remain on a stable dose for at least 2 weeks before enrollment (Day 1). Tapering post enrollment will be at PI's discretion.
Key Exclusion Criteria:
-
Participants with any of the following abnormal liver function tests in the presence of hepatobiliary IgG4-RD activity:
- aspartate aminotransferase (AST) > 10 × upper limit of normal (ULN)
- alanine aminotransferase (ALT) > 10 × ULN
- total bilirubin (TBL) > 5 × ULN Screening liver function tests may be repeated before Day 1 to permit abnormal values due to hepatobiliary IgG4-RD activity to respond to GC treatment.
-
Evidence of significant hepatic, renal, or metabolic dysfunction or significant hematological abnormality, including any of the following at screening (one repeat test may be conducted to confirm results within the same screening period):
- platelet count < 75000/μL (or < 75 × 109/L)
- absolute neutrophil count < 1200 cells/μL
- total Ig < 600 mg/dL
- CD4 T lymphocyte count < 300 cells/µL
- hemoglobin < 8 g/dL (or < 80 g/L).
-
Estimated glomerular filtration rate < 45 mL/min/1.73 m^2.
-
B-cell counts < one-half of the lower limit of normal (LLN) for age according to the central laboratory.
-
Diagnosed with a concurrent autoimmune disease that is uncontrolled or requires any prohibited medication (unless approved by the medical monitor).
-
Clinically significant serious active or chronic viral, bacterial, or fungal infection that requires treatment with anti-infectives, hospitalization, or, in the investigator's opinion, represents an additional risk to the participant, within 2 months before Day 1 of study.
-
Known history of congenital or acquired immunodeficiency (eg, due to human immunodeficiency virus [HIV] infection, splenectomy, immunosuppression-related or idiopathic T-cell deficiencies) that predisposes the participant to infection.
-
Positive test for chronic hepatitis B infection at screening, defined as either: (1) Positive hepatitis B surface antigen (HBsAg); or (2) Positive hepatitis B core antibody (anti-HBc) PLUS negative hepatitis B surface antibody (anti-HBs). Note: Participants with a positive anti-HBs only, or a positive anti-HBc plus positive anti-HBs and negative HBsAg, are eligible to enroll.
-
Receipt of any of the following before Day 1: alemtuzumab, total lymphoid irradiation, bone marrow transplant, T-cell vaccination therapy.
-
Receipt of any of the following within 2 months before Day 1: azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, cyclophosphamide, tocilizumab, satralizumab, eculizumab, and mitoxantrone.
-
Receipt of rituximab or any experimental B-cell depleting agent (eg, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab), or any non-depleting B-cell-directed therapy (eg, belimumab), abatacept, within 6 months before screening unless B-cell counts have returned to ≥ one-half the LLN.
-
Receipt of any live or attenuated vaccine (administration of inactivated [killed] vaccine is acceptable) within 4 weeks before Day 1, Bacillus Calmette-Guérin vaccine within 1 year of screening, or blood transfusion within 4 weeks before screening or during screening.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Inebilizumab
Participants will receive Inebilizumab via intravenous (IV) infusion. |
Inebilizumab will be administered via IV infusion. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Maksimal plasmakonsentrasjon (Cmax) av inebilizumab
Tidsramme: Opp til dag 561
|
Opp til dag 561
|
|
Areal under plasmakonsentrasjons-tidskurven (AUC) for inebilizumab
Tidsramme: Opp til dag 561
|
Opp til dag 561
|
|
Klaring (CL) av Inebilizumab
Tidsramme: Opptil dag 561
|
Opptil dag 561
|
|
Terminal halveringstid (t½) for inebilizumab
Tidsramme: Opp til dag 561
|
Opp til dag 561
|
|
Volum av distribusjon ved stabil tilstand (Vss) for Inebilizumab
Tidsramme: Opp til dag 561
|
Opp til dag 561
|
|
Endring fra baseline i CD20+ B-celleantall
Tidsramme: Utegning og dag 561
|
Utegning og dag 561
|
|
Antall deltakere som opplever bivirkninger (AEs)
Tidsramme: Opptil dag 561
|
Opptil dag 561
|
|
Antall deltakere som opplever alvorlige bivirkninger (SAE)
Tidsramme: Baseline opp til dag 561
|
Baseline opp til dag 561
|
|
Antall deltakere som opplever hendelser av interesse (EOI)
Tidsramme: Grunnlinje opp til dag 561
|
Grunnlinje opp til dag 561
|
|
Antall deltakere som opplever klinisk signifikante endringer fra utgangspunktet i laboratorieparametere
Tidsramme: Baseline opp til dag 561
|
Baseline opp til dag 561
|
|
Antall deltakere som opplever klinisk signifikante endringer fra utgangspunktet i vitale tegn
Tidsramme: Grunnlinje opp til dag 561
|
Grunnlinje opp til dag 561
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Tid til første behandlede flare over 52 uker
Tidsramme: Opptil uke 52
|
Opptil uke 52
|
|
Prosentandel av deltakere uten oppblussing over 52 uker
Tidsramme: Opptil uke 52
|
Opptil uke 52
|
|
Årlig flare-rate over 52 uker
Tidsramme: Opptil uke 52
|
Opptil uke 52
|
|
Tilstedeværelse av antidrug-antistoffer (ADA) før og etter oppstart av behandling
Tidsramme: Dag 1 til Dag 561
|
Dag 1 til Dag 561
|
|
Prosentvis reduksjon fra basislinje i daglig glukokortikoiddose ved uke 52
Tidsramme: Grunnlinje og uke 52
|
Grunnlinje og uke 52
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: MD, Amgen
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 20240202
- 2025-520988-41-00 (Ctis)
- 2025 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD-delingstidsramme
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Tilgangskriterier for IPD-deling
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .